Translating Immunotherapy Innovation Program

This program demonstrates a translational model where a new company forms to take immunotherapy-based innovations to market, and includes translational research undertaken by the founding CEO of TRI, Professor Ian Frazer. 

What are immunotherapies?

Immunotherapies are a type of 'biological therapy' that influence the immune system and help fight disease. They can work by stimulating the immune system to help your body to identify and target cancer cells, or in other cases may be used to suppress the immune system when it is over-active, such as for treatment of autoimmune disease. These therapies may be in the form of antibodies or vaccines, and can be highly effective for treating various diseases. 

Translating innovations into immunotherapies - to improve treatment options for patients

After a promising discovery is made in the lab, particular expertise and commercial knowledge is required to support further development, so the product can be taken 'to market'. 

To facilitate this process, forming a company, or partnering with an existing commercial company, can help 'translate' or move these discoveries into the clinic, where they can make a difference for patients. 

The Translating Immunotherapy Innovation Program 

The Translating Immunotherapy Innovation Program at TRI demonstrates a translational model where a new company is formed to take immunotherapy-based discoveries to market.

This Program features the following TRI-based companies who are achieving translational success and progressing their immunotherapy products through clinical trials:

Admedus Immunotherapies is a global medical technologies company based at TRI that is currently involved in demonstrating clinical proof of concept for a vaccine to treat HPV-associated head and neck cancers.

Check out the TRIangle Video Series: Episode 2 - Immunotherapies for Head and Neck Cancer to learn more about their work. 


Dendright is a clinical-stage biopharmaceutical company based at TRI developing an immunotherapy for rheumatoid arthritis.

Founded by UQ Professor Ranjeny Thomas, the team at Dendright have developed and patented a liposome vaccine strategy to induce antigen-specific tolerance in rheumatoid arthritis. To find out more about their technology, watch this video


Harnessing learnings from these experiences, we can use this knowledge to inform our approach to take further innovations to market, and improve health outcomes for patients across other disease areas.

Information about other TRI-based companies can be found here.